Info Obat dan Regulator Obat Dunia

F
Expanded Access Part 4: How to Complete Form FDA 3926 for Follow-up Submissions (September 2019)
Replies
0
Views
238
FDA
F
F
Vasyl Melnyk, M.D. - 623671 - 12/21/2021
Replies
0
Views
391
FDA
F
F
Amcyte Pharma, Inc. - 623474 - 01/03/2022
Replies
0
Views
330
FDA
F
F
Research in Progress | Office of Prescription Drug Promotion (OPDP) Research
Replies
0
Views
317
FDA
F
F
April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
Replies
0
Views
294
FDA
F
F
Products Claiming to "Cure" Cancer Are a Cruel Deception
Replies
0
Views
265
FDA
F
F
Reports & Budgets | CDER
Replies
0
Views
401
FDA
F
F
Public Meeting on Patient-Focused Drug Development for Vitiligo - 03/08/2021 - 03/08/2021
Replies
0
Views
359
FDA
F
F
Research Pending Peer Review and Publication | Office of Prescription Drug Promotion (OPDP) Research
Replies
0
Views
366
FDA
F
F
Generic Drugs Undergo Rigorous FDA Scrutiny
Replies
0
Views
276
FDA
F
F
Varigard, LLC - 616757 - 12/29/2021
Replies
0
Views
447
FDA
F
F
Withdrawn Guidances (Drugs)
Replies
0
Views
406
FDA
F
F
Providing Regulatory Submissions in Electronic Format -- Standardized Study Data
Replies
0
Views
407
FDA
F
F
FDA Voices on Medical Products
Replies
0
Views
291
FDA
F
F
Expiration Dates - Questions and Answers
Replies
0
Views
349
FDA
F
F
Taro Pharmaceuticals U.S.A. Issues Voluntary Nationwide Recall of Clobetasol Propionate Ointment USP, 0.05%, 60 g Tubes, Lot AC13786 Due to Microbial
Replies
0
Views
389
FDA
F
F
Guidance Recap Podcast: Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers
Replies
0
Views
368
FDA
F
F
Guidance Snapshot Pilot
Replies
0
Views
352
FDA
F
F
Public Meeting on the Recommendations for Biosimilar User Fee Act (BsUFA) Reauthorization - 11/02/2021 - 11/02/2021
Replies
0
Views
282
FDA
F
F
Medication Guides: Distribution Requirements for Health Care Professionals (March 2020)
Replies
0
Views
336
FDA
F
You must log in or register to post here.
Top